Penumbra (PEN)
(Delayed Data from NYSE)
$191.56 USD
-2.75 (-1.42%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $191.61 +0.05 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$191.56 USD
-2.75 (-1.42%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $191.61 +0.05 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection
by Zacks Equity Research
The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
CVS Health (CVS) Invests in Renewable Energy With New Pact
by Zacks Equity Research
CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).
Encompass Health's (EHC) 158th Hospital Opens in Maryland
by Zacks Equity Research
The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
by Zacks Equity Research
Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe
by Zacks Equity Research
Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
by Zacks Equity Research
Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
by Zacks Equity Research
Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.
Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI
by Zacks Equity Research
The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.
Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger
by Zacks Equity Research
Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.
Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture
by Zacks Equity Research
Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
UnitedHealth Group (UNH) Hikes Quarterly Dividend by 14%
by Zacks Equity Research
UnitedHealth Group's (UNH) recent dividend hike highlights a solid financial position and efforts to sustain its sound capital deployment history.
Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan
by Zacks Equity Research
Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.
Zacks.com featured highlights include Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop
by Zacks Equity Research
Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop are part of the Zacks Screen of the Week article.
Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
by Zacks Equity Research
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.